2024 Asia Conference on Lung Cancer (ACLC)
Conference | English | 2024
Image For Activity Cover
Cost
Regular Member: $150.00
Member - Other: $100.00
Non-Member: $200.00
Member - Developing Country: $50.00
Non-Member - Developing Country: $100.00
Free: $0.00
Credit Offered
23 Certificate of Attendance Credits

The IASLC 2024 Asia Conference on Lung Cancer, October 17-19, 2024, in Hong Kong, will bring together esteemed experts and leaders from around the world to share insights, exchange knowledge, and explore emerging trends within the field of lung cancer research and treatment.

This conference serves as a premier platform for showcasing the latest advancements in clinical and basic research, clinical management, and multidisciplinary care in the realm of lung cancer. 

The conference is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.
Upon completion of this activity, the participants should be able to: 
  • Examine scientific advances in thoracic cancer to make evidence-based diagnosis and treatment decisions.
  • Synthesize cutting edge research from clinical trials and translational studies to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
  • Support lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, addressing the quality and value of healthcare, and implementing early screening.
  • Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage patients.
  • Employ multidisciplinary teams to improve patient outcomes through patient-centered diagnostic, therapeutic and palliative care.
  • Support and empower patients to become active participants in their treatment.  
Program Co-Chairs:
  • Deepali Jain, MD, FIAC, FRCPath
  • Feng-Ming (Spring) Kong, MD, PhD, FACR, FAAWR, FASTRO
  • Tetsuya Mitsudomi, MD, PhD
  • Jie Wang, MD, PhD
  • James Chih-Hsin Yang, MD, PhD
The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
If you need assistance with this activity, please email: education@iaslc.org
Powered By